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Abstract
Cardiomyocyte-restricted overexpression of FK506-binding protein 12 transgenic (αMyHC-FKBP12) mice
develop spontaneous atrial fibrillation (AF). The aim of the present study is to explore the mechanisms
underlying the occurrence of AF in αMyHC-FKBP12 mice. Spontaneous AF was documented by telemetry
in vivo and Langendorff-perfused hearts of αMyHC-FKBP12 and littermate control mice in vitro. Atrial
conduction velocity was evaluated by optical mapping. The patch-clamp technique was applied to
determine the potentially altered electrophysiology in atrial myocytes. Channel protein expression levels
were evaluated by Western blot analyses. Spontaneous AF was recorded in four of seven αMyHC-FKBP12
mice but in none of eight nontransgenic (NTG) controls. Atrial conduction velocity was significantly
reduced in αMyHC-FKBP12 hearts compared with NTG hearts. Interestingly, the mean action potential
duration at 50% but not 90% was significantly prolonged in αMyHC-FKBP12 atrial myocytes compared
with their NTG counterparts. Consistent with decreased conduction velocity, average peak Na  current
(I ) density was dramatically reduced and the I  inactivation curve was shifted by approximately +7 mV
in αMyHC-FKBP12 atrial myocytes, whereas the activation and recovery curves were unaltered. The
Na 1.5 expression level was significantly reduced in αMyHC-FKBP12 atria. Furthermore, we found
increases in atrial Ca 1.2 protein levels and peak L-type Ca  current density and increased levels of
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fibrosis in αMyHC-FKBP12 atria. In summary, cardiomyocyte-restricted overexpression of FKBP12
reduces the atrial Na 1.5 expression level and mean peak I , which is associated with increased peak
L-type Ca  current and interstitial fibrosis in atria. The combined electrophysiological and structural
changes facilitated the development of local conduction block and altered action potential duration and
spontaneous AF.
NEW & NOTEWORTHY This study addresses a long-standing riddle regarding the role of FK506-
binding protein 12 in cardiac physiology. The work provides further evidence that FK506-binding protein
12 is a critical component for regulating voltage-gated sodium current and in so doing has an important role
in arrhythmogenic physiology, such as atrial fibrillation.
Keywords: action potential duration, cardiac electrophysiology, fibrosis, ion channels, patch clamp,
voltage-gated sodium current
INTRODUCTION
Atrial fibrillation (AF) is the most common type of cardiac arrhythmia and is associated with substantial
morbidity and mortality (11, 13). Ion channelopathies are major contributing factors to AF (2). Among the
different ionic currents, abnormal Na  currents (I ) are known to be causally related to AF (5, 9). Na
channel remodeling is a typical pathophysiological alteration that occurs in AF (28, 35). Cardiac voltage-
gated Na  channels determine the amplitude and slope of the action potential (AP) upstroke in atrial and
ventricular cardiomyocytes and are responsible for the generation of the inward I  that underlies
excitability and conduction in the working myocardium and conduction system cells (8). Mutations in
genes encoding cardiac voltage-gated Na  channels (e.g., SCN5A) and their functional regulators are
associated with multiple forms of arrhythmogenic syndromes (23) and AF (9). Six percent of AF cases are
associated with rare genetic variants of SCN5A, a gene coding the Na 1.5 α-subunit (7). For example, the
loss-of-function mutation (e.g., Brugada syndrome) (3) and gain-of-function mutation of cardiac voltage-
gated Na  channels are both associated with familial AF (23). Transgenic mice with overexpression of loss-
of-function mutant SCN5A display spontaneous AF (33), highlighting the importance of I  in the
generation of AF.
Recently, we identified a novel physiological function for FK506-binding protein 12 (FKBP12) in
regulating cardiac voltage-gated Na  channels. FK506 (Tacrolimus) is a potent immunosuppressant drug
and is used to prevent host-to-donor tissue rejection in organ transplant patients. However, it has been well
documented that FK506 causes arrhythmias, including sinus arrest, long QT syndrome, and sudden death
(6, 12, 25), yet the mechanism of this action is not clear. FKBP12 is a cytoplasmic peptidyl-prolyl cis-trans
isomerase and is highly expressed in cardiomyocytes. Previously, it has been shown that FKBP12 regulates
the skeletal muscle Ca -release channel ryanodine receptor (RyR)1 and excitation-contraction coupling in
skeletal muscle (18). However, its function in cardiomyocytes was largely unknown, although FKBP12 is
highly expressed in both atrial and ventricular myocytes. Previously, we have shown that ablation of
FKBP12 in the heart leads to a greater than twofold increase in peak I  density in mouse ventricular
cardiomyocytes; in contrast, ventricular cardiomyocytes isolated from transgenic mice with cardiac-
restricted overexpression of FKBP12 (αMyHC-FKBP12) exhibited a dramatic reduction in peak I
density and showed significantly reduced ventricular conduction velocity (17). These data suggest that
FKBP12 is an important regulator for Na 1.5.
In addition to changes in the ventricles, we recently found that αMyHC-FKBP12 mice also develop AF
during electrophysiological studies and during telemetry ECG monitoring. It has been shown that
functional and anatomic reentries are important mechanisms for the occurrence of AF. Either increased
atrial size or shortened impulse wavelength by decreased conduction velocity and/or refractory period
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αMyHC-FKBP12 mice.
Telemetric ECG analyses.
Optical mapping experiment in Langendorff-perfused hearts.
Cell isolation.
Whole cell patch-clamp recording.
Western blot.
facilitates the formation of multiple wavelets and occurrence of AF (2). The present study aimed to explore
potential mechanism that underlies the development of spontaneous AF in these mice. Specifically, we
performed a series of optical mapping and patch-clamp experiments and found several unique alterations in
electrophysiology and histology in αMyHC-FKBP12 atria that may explain the occurrence of AF in
αMyHC-FKBP12 hearts.
METHODS
The animal study protocols were approved by the Institutional Animal Care and
Use Committee of Indiana University and the Methodist Research Institute and conformed with the
National Institutes of Health Guide for the Care and Use of Laboratory Animals. The αMyHC-FKBP12
transgenic mice used in this study were generated as previously described (17). The mice used for
monitoring and optical mapping were 2–4 mo old.
Telemetric analysis of ECGs was performed on the PhysioTel Telemetry system
(Data Sciences, St. Paul, MN) (17). Briefly, mice were lightly anesthetized with 1.5% isoflurane. The
subcutaneous leads were surgically placed over the scapula in a lead II configuration. The continuous data
recordings were allowed using hardware modification in the waveform format from multiple instrumented
mice. The data were collected using an implantable radiofrequency microtransmitter (TA1010ETA-F20)
and then analyzed using Dataquest A.R.T. version 4.1.
Hearts were perfused with a Langendorff
perfusion system with 37°C Tyrode solution [containing (in mmol/l) 125 NaCl, 4.5 KCl, 1.8 NaH PO , 24
NaHCO , 1.8 CaCl , 0.5 MgCl , and 5.5 glucose] with pH equilibrated to 7.40 ± 0.05 at a flow rate of ≈2
ml/min. Optical mapping of voltage-dependent signals was performed to measure atrial conduction
velocities as previously described (17) with minor modifications. The emitted fluorescence was collected
using a high-speed CMOS camera (MiCAM Ultima, BrainVision, Tokyo, Japan) at 0.2 ms/frame and 100 ×
100 pixels with spatial resolution of 0.07 × 0.07 mm /pixel. The preparation was paced from the edge of
the right atrial appendage. The conduction time from the stimulus to the completion of the activation of
both atria was determined. The conduction velocity was the ratio between the distance from the pacing site
to the site of the latest atrial activation and the activation time.
Left atrial and ventricular cardiomyocytes were isolated from Langendorff-perfused mouse
hearts as previously described (16). Single rod-shaped cells with clear cross striations were used for
electrophysiological recording. We used only left atrial cardiomyocytes to keep the electrophysiological
and biological consistency of cells from each experiment.
Whole cell patch-clamp recordings were performed with an Axopatch
700B amplifier (Axon Instruments). I  was recorded at room temperature (~22°C). Ca  currents were
recorded at 37°C. Tetrodotoxin (5 µM) was added to block I  when recording Ca  currents. AP duration
(APD) was recorded at 37°C under current-clamp mode in normal Tyrode solution. Current-amplitude data
of each cell were normalized to its cell capacitance (current density; in pA/pF), and the current-voltage (I-
V) relationship (I-V curve) was plotted. Voltage-dependent activation and steady-state inactivation profiles
were fitted to the following Boltzmann equation: a = 1/{1 + exp[−(V  − V )/k]}, where a is the normalized
conductance, V  is the test potential, V  is the potential at which current is half activated/inactivated, and k
is the slope factor.
Western blots were performed as previously described (17). Rabbit polyclonal FKBP12
antibody (catalog no. ab2918, 1:2,000) was from Abcam. Rabbit polyclonal Ca 1.2 antibody (catalog no.
C1241, 1:200) was from Sigma. Antibody against Na 1.5 (1:1,500) was kindly provided by Dr. Peter
Mohler (Ohio State University).
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Histological analyses.
Statistical analysis.
Paroxysmal AF in αMyHC-FKBP12 mice.
Impaired atrial conduction and prolonged APD in αMyHC-FKBP12 mice.
Decreased I  in atrial myocytes of αMyHC-FKBP12 mice.
Hearts were fixed with 10% neutral buffered formalin. Tissues were processed
routinely and embedded in paraffin. Sections were stained with hematoxylin and eosin or picrosirius red for
histological examination. Custom-written Magic Wand software was used to identify and quantitate the
extent of fibrosis.
Continuous variables are presented as means ± SE. Nonparametric tests were used to
compare the means between groups. Fisher’s exact test was used to compare the occurrence of AF between
groups. P ≤ 0.05 was considered statistically significant.
RESULTS
As we have previously described, by Western blot analyses, we
have further confirmed that FKBP12 is overexpressed in αMyHC-FKBP12 atria ~11-fold compared with
nontransgenic (NTG) controls (Fig. 1). Seven αMyHC-FKBP12 and eight NTG control mice were
subjected to radiotelemetric ECG recordings. Paroxysmal AF was documented during telemetric
monitoring in four of seven αMyHC-FKBP12 mice (Fig. 2, A and B) but in none of eight NTG control mice
(P = 0.03). The rhythm shown in Fig. 2A demonstrates that the initial phase of the tachycardia (line 2)
consists of slower but irregular rhythm, with variable P waves. This initial phase of rhythm might be
consistent with multifocal atrial tachycardia. The rhythm then degenerated into AF with more rapid
atrioventricular conduction (line 3). To better understand this arrhythmogenic phenotype, we performed
electrophysiological experiments using Langendorff-perfused hearts (Fig. 2C). Spontaneous AF was
observed in three of eight αMyHC-FKBP12 hearts during the electrophysiological experiments but in none
of eight NTG hearts. There were prolonged sinus pauses after cessation of paroxysmal AF, resembling
tachybrady syndrome in humans. As shown in our previous work (17), the heart rate of αMyHC-FKBP12
mice was 222 ± 35 beats/min, which was significantly slower compared with that measured in NTG control
mice (472 ± 29 beats/min).
To determine the underlying
electrophysiological mechanism for the occurrence of AF in FKBP12 transgenic mice, we first measured
conduction velocity in atria using the optical mapping technique. The conduction velocity of the atria was
significantly decreased in αMyHC-FKBP12 hearts (n = 8) compared with NTG littermate control hearts (n
= 6, 0.22 ± 0.03 vs. 0.71 ± 0.08 m/s, P < 0.05; Fig. 3, A and B). We further compared the APD of isolated
single left atrial cells from NTG and αMyHC-FKBP12 hearts using the whole cell patch-clamp technique.
We found that mean APD at 50% repolarization increased from 6.58 ± 0.61 ms in NTG hearts to 23.9 ± 5.4
ms in αMyHC-FKBP12 hearts (P < 0.05; Fig. 3, C and D); however, mean APD at 50−70% and 90%
repolarization was not significantly different (Fig. 3, E and F). The mean phase 0 overshoot of the AP
decreased from 42.8 ± 1.7 mV in NTG hearts to 16.9 ± 3.4 mV in αMyHC-FKBP12 hearts (P < 0.05;
Fig. 3G), suggesting that the altered I  underlies the abnormal cardiac physiology in transgenic mice.
To determine I  properties in atrial cells,
whole cell I  was evaluated in αMyHC-FKBP12 and littermate control atrial cardiomyocytes. I  was
elicited during 50-ms square-wave voltage steps to various test potentials ranging from −90 to +30 mV (5-
mV increments, holding potential: −100 mV, interpulse interval: 1.0 s) in NTG and αMyHC-FKBP12 atrial
cardiomyocytes (Fig. 4A). Mean peak I  density was dramatically reduced in atrial cardiomyocytes from
αMyHC-FKBP12 mice (n = 15 cells/3 mice) compared with NTG mice (n = 20 cells/4 mice, 38.7 ± 5.8 vs.
97.2 ± 5.8 pA/pF, P < 0.05; Fig. 4, B and C), which is consistent with the finding in ventricular
cardiomyocytes. The voltage dependence of steady-state inactivation of I  was shifted toward more
positive potentials in αMyHC-FKBP12 cardiomyocytes (V : −91.1 ± 2.9 mV in αMyHC-FKBP12 mice
vs. −84.4 ± 4.4 mV in NTG mice, P < 0.05; Fig. 4D), whereas the activation and recovery curves showed
no apparent alteration in αMyHC-FKBP12 compared with control atrial cardiomyocytes (Fig. 4, D and E).
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L-type Ca  current and K  currents in atrial cardiomyocytes of αMyHC-FKBP12 mice.
Expression of Na 1.5 and Ca 1.2 in atria of αMyHC-FKBP12 mice.
Altered atrial histology in αMyHC-FKBP12 hearts.
Changes of I .
Interestingly, in contrast to our previous observation in transgenic ventricular cardiomyocytes, we did not
observe a significant increase of late I  in atrial cardiomyocytes (not shown), suggesting cell type-specific
regulation of I . The lack of late I  may explain the normal APD at 90% repolarization in αMyHC-
FKBP12 atrial cardiomyocytes.
As APD at
50% repolarization is prolonged, we postulated that other ion currents contributing to repolarization were
altered. Thus, we specifically recorded L-type Ca  current (I ) and K  currents. Interestingly, in
contrast to the reduced peak I  density in αMyHC-FKBP12 ventricular cardiomyocytes, mean peak
I  density was found to be significantly increased in αMyHC-FKBP12 atrial cardiomyocytes (13 cells/4
mice) compared with NTG atrial cardiomyocytes (10 cells/4 mice, 18.4 ± 1.9 vs. 10.1 ± 0.7 pA/pF, P <
0.05; Fig. 5, A–C). I  properties, including activation, inactivation, and recovery from inactivation,
showed no apparent alterations (Fig. 5, D and E, and Table 1). We also evaluated transient outward K
current (I ), sustained K  current (I ), and inwardly rectifying K  current (I ) in αMyHC-FKBP12
atrial cardiomyocytes. FKBP12 overexpression produced no significant influence on I , I , and I
densities (Fig. 6).
To further evaluate the molecular
basis for reduced I  and increased I , we examined the level of Na 1.5 (the pore-forming subunit of the
major cardiac voltage-gate Na  channel) and Ca 1.2 (the pore-forming subunit of cardiac L-type Ca
channels) by Western blot analysis. Consistent with the decreased peak I  density, we found that the
protein level of Na 1.5 in αMyHC-FKBP12 atria was reduced by 7.7-fold compared with NTG atria (P <
0.05; Fig. 7A). Interestingly, in contrast to the normal expression level in ventricles, the Ca 1.2 protein
expression level showed a significant 2.5-fold increase in αMyHC-FKBP12 atria compared with NTG
control atria (Fig. 7B).
We further evaluated the atrial anatomy of αMyHC-
FKBP12 hearts. We not only confirmed that both atria of αMyHC-FKBP12 hearts were enlarged but also
found that both atria of αMyHC-FKBP12 hearts were significantly more fibrotic compared with NTG
littermate control hearts (Fig. 8, A and B) Picrosirius red staining showed that the amount of fibrosis was
dramatically increased in the atria of αMyHC-FKBP12 mice (8 wk old) compared with NTG littermates (
Fig. 8, C–F). The fibrotic areas were 0.42 ± 0.45% in NTG littermates and 2.17 ± 0.98% in αMyHC-
FKBP12 mice (P < 0.05).
DISCUSSION
FKBP12 is a cardiac enriched protein. We have previously shown that FKBP12 plays an important role in
cardiac development (27) and ventricular conduction defects (17). In this study, we found that FKBP12
overexpression also causes changes of atrial electrophysiology and facilitates the development of
spontaneous AF. The most prominent changes of ion channel expression include reduced peak I  and
increased peak I . In contrast to the findings in ventricular cardiomyocytes, late I  was not increased in
atrial cardiomyocytes. These findings show that chronic FKBP12 overexpression has differential effects on
the electrophysiological characteristics of atrial and ventricular cardiomyocytes.
Functional and anatomic reentry is an important mechanism of AF. Either increased atrial
size or shortened impulse wavelength by decreased conduction velocity and/or refractory period facilitates
the formation of multiple wavelets and occurrence of AF (2). In the present study, we found that the atria
were enlarged and atrial conduction velocity in αMyHC-FKBP12-overexpressing mice was slower than in
NTG control mice. A major determinant of electrical conduction in the atria is the magnitude of Na  influx
through voltage-gated Na  channels during the initial fast membrane depolarization (14). Consistent with a
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Increased Ca  current.
Interstitial fibrosis.
reduced conduction velocity, we found that there was reduced peak I  and downregulation of Na 1.5
protein in transgenic mice compared with NTG control mice. The increased availability of the Na  channel
in αMyHC-FKBP12 transgenic mice resulting from a positive shift of the inactivation curve was apparently
insufficient to compensate for the reduction in peak I . Moreover, the positive shift of the I  inactivation
curve causes an increase in steady-state (“window”) current, which may contribute to the APD
prolongation. I  was reduced in atrial cardiomyocytes from patients with AF (28) and from dogs with
pacing-induced AF (35). Watanabe et al. (33) established a knockin mouse model carrying the human
D1275N-SCN5A mutation. They observed I  reduction, conduction slowing, and AF occurrence. These
findings provide direct evidence for the causal role of reduced Na  channel function and the mechanisms of
AF.
Although we (17) and others (22, 30) showed that simultaneous increment of late I  may accompany
reduced peak I , no increase of late I  density was observed in atrial cardiomyocytes of αMyHC-
FKBP12 mice. Previous studies have documented different expression of ion channel genes and differential
regulation of channels in atrial and ventricular cardiomyocytes (21), which may lead to significant
differences of the biophysical characteristics of I . For example, the half-inactivation voltage of I  was
more negative in atrial versus ventricular cardiomyocytes (4, 15). Recovery of I  from inactivation was
slower in atrial cardiomyocytes than in ventricular cardiomyocytes, whereas the development of resting
state inactivation was more rapid in atrial cardiomyocytes than in ventricular cardiomyocytes (15). These
biophysical differences of atrial and ventricular I  may in part account for the differential effects of
FKBP12 overexpression on late I .
An unexpected finding in this study was that I  is increased in atrial
cardiomyocytes of transgenic mice compared with NTG control mice. Ca  influx during the AP plateau is
important in determining APD. An increase of I , an inward current, tends to keep the cell depolarized
and prolongs APD (20). Ca  also activates cardiac RyR2 to release Ca  from the sarcoplasmic reticulum.
The latter process may also be in part controlled by FKBP12 (10, 26). In the present study, we recorded a
significant increase of I  density in atrial cardiomyocytes of αMyHC-FKBP12 mice, with no channel
kinetic alterations. This augmentation of I  can be explained by the concurrent upregulation of Ca 1.2,
the pore-forming protein of the Ca  channel. We think that one possible mechanism of Ca 1.2
upregulation is that FKBP12 directly upregulates Ca 1.2 production. However, there are no data to support
this hypothesis. An alternative explanation is a secondary event due to the atrial enlargement based on the
following: 1) short-term overexpression of FKBP12 in rabbit ventricular myocytes by adenoviral system
produced no changes in I  (26); 2) acute treatment of FK506 did not alter I  densities and I-V
relationships in either rabbit, rat, or mouse ventricular cardiomyocytes (19, 29, 34); and 3) I  did not
change in ventricular cardiomyocytes of αMyHC-FKBP12 mice from the same line as used in the present
study (17). Because the latter study recorded I  at room temperature while the present study recorded
I  at 37°C, it is possible that the different recording temperatures played a role in these findings.
Therefore, we repeated the patch-clamp experiments of ventricular cardiomyocytes at 37°C. The results
showed no change of I  in αMyHC-FKBP12 ventricular cardiomyocytes (not shown) (4). I  is often
increased in models of mild to moderate hypertrophy (1). The αMyHC-FKBP12 mouse has significantly
enlarged atria but not ventricles. The differential expression of I  in atrial and ventricular
cardiomyocytes may be due to the greater pathological effects of FKBP12 overexpression on the atria than
ventricles. However, the mechanism by which FKBP12 induced atrial but not ventricular enlargement
remains unclear. The relationship between atrial enlargement and I  upregulation is also unclear.
Interstitial fibrosis is an important contributor to the AF substrate and may affect atrial
conduction (20). We found that there was significantly more atrial fibrosis in αMyHC-FKBP12 mice than
in NTG mice. The increased fibrosis may contribute to the mechanisms of AF. A direct effect of FKBP12 is
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Conclusions.
unlikely as the cause of atrial fibrosis, because FKBP12 inhibits the transforming growth factor-β type I
receptors (32). Because previous studies have documented increased fibrosis in mice with SCN5A mutation
(24, 31), it is possible that reduced I  and Na 1.5 in FKBP12 transgenic mice caused increased fibrosis in
the atria. The molecular mechanisms by which FKBP12 regulates Na 1.5 biochemically remain
undetermined.
In summary, we found that FKBP12 overexpression in the mouse heart caused enlarged
atria, atrial fibrosis, reduced peak I  density, and enhanced peak I  density in atrial cardiomyocytes,
which, in turn, decreased atrial conduction velocity and prolonged APD. These morphological and
electrical alterations facilitated the development of spontaneous AF.
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Fig. 1.
Open in a separate window
Protein level of FK506-binding protein 12 (FKBP12) in the atria of FKBP12 transgenic (αMyHC-FKBP12) mice.
Endogenous FKBP12 (Endo) and overexpressed transgenic flag-FKBP12 (Flag) are indicated by arrows. WT, wild type.
Data are expressed as means ± SE; n = 4. *P < 0.05 vs. nontransgenic (NTG) mice.
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Fig. 2.
Atrial fibrillation (AF) in FK506-binding protein 12 transgenic (αMyHC-FKBP12) mice. A: paroxysmal AF documented
by ambulatory ECG. B: the diagnosis of AF was supported by the absence of P waves despite the presence of clear P
waves during sinus rhythm and irregular rhythm, which was evident in the 5-min cycle length histogram. C: AF occurred
spontaneously during the electrophysiological experiment (top traces). Note that the termination of AF was followed by
prolonged sinus pause (bottom traces), suggesting abnormal sinus node function. AE, atrial ectopy; pECG, pseudo ECG;
iECG, intracardiac electrograms.
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Fig. 3.
Conduction velocity (CV) and action potential (AP) duration (APD) in the atria of FK506-binding protein 12 transgenic
(αMyHC-FKBP12) mice. A: representative pictures of AP propagation in the atria by optical mapping. Scale bar = 2 mm.
B: comparison of atrial CV between αMyHC-FKBP12 and nontransgenic (NTG) control mice. C: representative AP traces
in single atrial myocytes. D–G: comparison of APD at 50%, 90%, and 50-70% repolarization (APD , APD , and
APD , respectively) and the AP overshoot between atrial myocytes from αMyHC-FKBP12 (n = 19 cells/4 mice) and
NTG control mice (n = 24 cells/4 mice). WT, wild type. Data are expressed as means ± SE. *P < 0.05 vs. NTG mice.
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Fig. 4.
Analysis of Na  currents (I ) of isolated atrial cardiomyocytes in nontransgenic (NTG) and FK506-binding protein 12
transgenic (αMyHC-FKBP12) mice. A: representative tracings of total I . B: peak I  density from NTG (n = 20 cells/4
mice) and αMyHC-FKBP12 (n = 15 cells/4 mice) atrial myocytes. C: current-voltage (I-V) relationship (I-V curve) for
peak I  density. D: voltage dependence of the steady-state activation and inactivation for I . For activation, the cell was
held at −100 mV and depolarized for 50 ms to potentials between −90 and +10 mV in 5-mV increments. The interpulse
interval was 1 s. For inactivation, the cell was held at −100 mV, and 1-s preconditioning pulses to potentials between −120
and −30 mV in 5-mV increments were applied followed by 40-ms test pulses to −25 mV. The interpulse interval was 3 s.
E: time course of I  recovery from inactivation. Recovery was recorded by depolarizing the cell to −30 mV from the
holding potential of −100 mV for 300 ms (P1) followed by a variable recovery interval and a subsequent −30-mV test
pulse (P2). *P < 0.05 vs. NTG mice.
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Fig. 5.
Analysis of cardiac L-type Ca  currents (I ) from isolated atrial cardiomyocytes in nontransgenic (NTG) and FK506-
binding protein 12 transgenic (αMyHC-FKBP12) mice. A: representative traces of whole cell I . B: peak I  density
in NTG (n = 12 cells/4 mice) and αMyHC-FKBP12 (n = 13 cells/4 mice) atrial myocytes. C: current-voltage (I-V)
relationship (I-V curve) for peak I . D: voltage dependence of the steady-state activation and inactivation for I . For
activation, the cell was held at −50 mV, ramp depolarized from −80 to −50 mV over 100 ms, and step depolarized from
−50 to +60 mV with 5-mV increments. The interpulse interval was 2 s. For inactivation, the cell was held at −50 mV, and
2,000-ms preconditioning pulses to potentials from −80 to −10 mV with a 5-mV increment were applied followed by a
300-ms test pulse to −10 mV. E: normalized peak I  (I/I ) for I  recovery from inactivation. Inset: recording
protocol. *P < 0.05 vs. NTG mice.
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Table 1.
Properties of I  and I  in atrial myocytes
Nontransgenic αMyHC-FKBP12
I
    Peak current density, pA/pF 97.2 ± 5.8 (n = 20) 38.7 ± 5.8  (n = 15)
    Activation
        V , mV −45.7 ± 1.0 (n = 12) −43.1 ± 1.2 (n = 13)
        k, mV 6.54 ± 0.23 (n = 12) 6.52 ± 0.38 (n = 13)
    Inactivation
        V , mV −92.1 ± 1.03 (n = 11) −84.4 ± 4.4  (n = 13)
        k, mV 10.16 ± 0.85 (n = 11) 9.27 ± 0.41 (n = 13)
I
    Peak current density, pA/pF 10.5 ± 0.66 (n = 12) 18.4 ± 1.91  (n = 13)
    Activation
        V , mV −5.44 ± 0.39 (n = 12) −7.56 ± 0.88 (n = 13)
        k, mV 6.78 ± 0.34 (n = 12) 5.88 ± 0.19 (n = 13)
    Inactivation
        V , mV −27.1 ± 0.27 (n = 12) −25.9 ± 1.02 (n = 12)
        k, mV 5.85 ± 0.23 (n = 12) 4.93 ± 0.20 (n = 12)
Values are means ± SE; n = number of cells from 4 mice. I , Na  current; I , L-type Ca  current; αMyHC-
FKBP12, FK506-binding protein 12 transgenic mice; V , midpoint voltage of maximal conductance/currents; k, slope
factor.
P < 0.05 vs. nontransgenic mice.
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Fig. 6.
Analysis of cardiac transient outward K  currents (I ), sustained K  currents (I ), and inward rectifier K  currents
(I ) from isolated atrial cardiomyocytes in nontransgenic (NTG) and FK506-binding protein 12 transgenic (αMyHC-
FKBP12) mice. A: representative I  traces of NTG and αMyHC-FKBP12 myocytes. I  was elicited from a holding
potential at −50 mV with a 50-ms ramp from −80 to −40 mV followed by depolarizing pulses from −40 to +50 mV for 625
ms (in 10-mV increments). B and C: current-voltage (I-V) relationship (I-V curve) for I  and I . NTG: n = 21 cells/4
mice and αMyHC-FKBP12: n = 14 cells/4 mice. D: representative I  traces of NTG and αMyHC-FKBP12 myocytes. I
was elicited by holding the cell at −40 mV followed by 10-mV steps from −120 to 50 mV for 300 ms. E: I-V curve for I .
NTG: n = 22 cells/4 mice and αMyHC-FKBP12: n = 18 cells/4 mice. WT, wild type.
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Fig. 7.
A and B: representative Western blots to analyze the expression of Na 1.5 (A) and Ca 1.2 (B) in the atria of FK506-binding
protein 12 transgenic (αMyHC-FKBP12) transgenic mice as evaluated by Western blot analysis. WT, wild type. *P < 0.05
vs. nontransgenic (NTG) mice.
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Fig. 8.
Open in a separate window
A–F: representative histological analysis of the atrial free wall stained with picrosirius red using conventional light (A–D)
and polarized light (E and F) from nontransgenic (NTG; A, C, and E) and FK506-binding protein 12 transgenic (αMyHC-
FKBP12; B, D, and F) mice. Note the larger atrial size and more abundant interstitial fibrosis in the αMyHC-FKBP12
mouse than in the NTG mouse. Bar = 20 µm. Fibrosis appears red in E and F. RA, right atria; LA, left atria.
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